GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM

Olivia Bennett
3 Min Read
Advertisement

GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM

GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM
Advertisement
GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM
Advertisement
GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, according to a research letter published online March 11 in JAMA Network Open.

Kuan-Yu Chi, M.D., from the Albert Einstein College of Medicine in Bronx, New York, and colleagues conducted a retrospective cohort study to examine the association between GLP-1 RA use and survival among patients with BM and T2D. The exposed cohort included adult patients prescribed GLP-1 RAs within six months before the first instance of T2D and BM diagnosis, while the control cohort had no GLP-1 RA use during the same period.

Advertisement

After propensity score matching, a total of 850 GLP-1 RA users were matched to nonusers among a total of 19,234 patients with cancer, BM, and T2D. The researchers found that all-cause mortality was significantly lower in association with GLP-1 RA use (hazard ratio, 0.63). The observed mortality benefit was consistent across major cancer types and GLP-1 RA types, apart from liraglutide, and compared with other antidiabetes therapies.

“These results build upon existing evidence that GLP-1 receptor activation modulates pathways relevant to neuro-oncologic health, including attenuation of neuroinflammation, preservation of blood-brain barrier integrity, and reduction of oxidative stress and mitochondrial dysfunction,” the authors write.

Publication details

Kuan-Yu Chi et al, GLP-1 Receptor Agonist Use and Survival Among Patients With Type 2 Diabetes and Brain Metastases, JAMA Network Open (2026). DOI: 10.1001/jamanetworkopen.2026.1311

Journal information:
JAMA Network Open

Key medical concepts

GLP-1 Receptor Agonist [EPC]Brain MetastaseDiabetes Type 2All-Cause MortalityNeuroinflammations

Clinical categories

OncologyEndocrinology

Copyright © 2026 HealthDay. All rights reserved.

Citation:
GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM (2026, March 13)
retrieved 13 March 2026
from https://medicalxpress.com/news/2026-03-glp-receptor-agonists-linked-mortality.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

📰 This article was curated and published by
HEALTH GUIDANCE HUB
— your trusted source for the latest health news, medical research, and wellness guidance.

Visit us at https://healthguidancehub.space/ for more health insights.

Share This Article
Follow:
Olivia Bennett (she/her) is a health education specialist and medical writer dedicated to providing clear, evidence-based health information. She holds a strong academic background in public health and clinical sciences, with advanced training from respected institutions in the United States and the United Kingdom.   Bennett earned her Bachelor of Science in Public Health from the University of Michigan. She later completed her Doctor of Medicine (MD) at the Johns Hopkins University School of Medicine, where she developed a deep interest in preventive care and patient education.   To further strengthen her expertise in global and community health, she obtained a Master of Science in Global Health and Development from the University College London. She also completed a Postgraduate Certificate in Clinical Nutrition at the King's College London.   Since completing her studies, Bennett has worked in both clinical and health communication roles, contributing to medical blogs, health platforms, and public awareness campaigns. Her work focuses on translating complex medical research into practical guidance that everyday readers can understand and apply.   In 2021, she began specializing in digital health education, helping online health platforms maintain medically accurate, reader-friendly content. Her key areas of focus include: Preventive healthcare Women’s health Mental health awareness Chronic disease management (diabetes, hypertension) Nutrition and lifestyle medicine   Bennett believes that trustworthy health information should be accessible to everyone. Her goal is to empower readers to make informed decisions about their well-being through clear, compassionate, and research-backed guidance.   Outside of her professional work, she enjoys reading medical journals, participating in community wellness initiatives, and mentoring aspiring health writers.
Leave a Comment